To this end, we developed a novel chimeric receptor that can recognize CD80 and CD86 as tumor antigens on malignant B cells by combining the extracellular and transmembrane domains of CTLA4 with the intracellular signaling domains of CD28 and CD3z and explored its potential in cancer treatment. Here, CD80 is linked to neoplasm.